All eyes on Gilead
With antiviral drug remdesivir granted emergency approval, are they ready for the challenge? The early results in COVID-19 patients treated with remdesivir showed a positive, if yet still cautious picture about the potential of the antiviral drug as the first effective treatment for this pandemic. Robert Langreth, writing in Bloomberg Businessweek, looks into the preparations of its maker, Gilead Sciences, to potentially satisfy global demand.
From Bloomberg Businessweek